Targeting Trabecular Meshwork Metabolism - Takeaways - MDSpire

Targeting Trabecular Meshwork Metabolism

Study suggests potential new vitamin B3 treatment for glaucoma protection

  • March 5, 2026

  • 5 min

Share

  • 1

    The study identified three distinct trabecular meshwork cell subtypes, revealing significant cellular diversity and specialization.

  • 2

    A specific cell subtype, TM3, is metabolically vulnerable and linked to intraocular pressure elevation in a glaucoma mouse model.

  • 3

    Vitamin B3 (nicotinamide) supplementation mitigates mitochondrial dysfunction in TM3 cells, preventing glaucoma-related pressure elevation.

  • 4

    The findings suggest that therapies targeting cellular metabolism, like nicotinamide, could serve as new treatments for glaucoma.

  • 5

    Future research will compare mouse TM cell subtypes to human counterparts to identify potential therapeutic targets for glaucoma.

Original Source(s)

Targeting Trabecular Meshwork Metabolism

  • March 5, 2026

Related Content

ASCRS 2026: Gonioscopy Still Matters

At the ASCRS Subspecialty Day, Ramya Swamy, MD explained that, despite advances in imaging, direct visualization of the angle remains central to care

  • April 14, 2026

  • 3 min
The Myopia Control Kit

Thomas Aller, OD, provides in-depth overviews of each myopia management option—pharmacologic therapy, soft contact lenses, orthokeratology, spectacle lenses, and environmental and behavioral interventions—so clinicians can not only provide the right option to each patient, but also address the larger economic and societal burdens of myopia.

Women in Glaucoma: Letter From the Editor

A panel of women in glaucoma shared personal experiences that have guided their approaches to surgical innovation, patient care, and mentorship, offering lessons that can inspire colleagues at every stage of their careers.